MVM Life Science Partners, Apposite Capital and Novo co-led an initial £10.3m first round of funding in the company in July 2007. US venture firm East Hill, which became a shareholder in Serentis following the acquisition of Surface Therapeutics in 2007, also participated in the financing.
Serentis is developing a pipeline of products for the treatment of various dermatological conditions.
“Since our initial financing a year ago, Serentis has made significant progress in identifying and developing our pipeline,” says Serentis CEO and co-founder Tim Sharpington.
“These funds will enable us to move our lead products towards key clinical milestones and to identify additional targets.”
Share this story